13.55

0.59% 0.08

After Hours: 13.31 -0.24 -1.77%

Immunome Inc (IMNM)

Overview News Price History Option Chain Financials Discussions Forecast

Immunome Inc stock is traded at $13.55, with a volume of 435.22K. It is up +0.59% in the last 24 hours and up +11.07% over the past month. Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Previous Close:

$13.47

Open:

$13.44

24h Volume:

435.22K

Relative Volume:

0.59

Market Cap:

$845.75M

Revenue:

Net Income/Loss:

$-106.81M

P/E Ratio:

-6.1591

EPS:

-2.2

Net Cash Flow:

$-8.40M

1W Performance:

+37.98%

1M Performance:

+11.07%

6M Performance:

-7.32%

1Y Performance:

+80.67%

1-Day Range:

$13.08

$13.66

1-Week Range:

$10.67

$13.66

52-Week Range:

$6.93

$30.96

Immunome Inc Stock (IMNM) Company Profile

Name

Immunome Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

610-321-3700

Address

18702 N. CREEK PARKWAY, BOTHELL

Employee

105

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IMNM's Discussions on Twitter

Compare IMNM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMNM Immunome Inc	13.55	845.75M	0	-106.81M	-8.40M	-3.3117
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Overweight
May-31-24	Initiated	Piper Sandler	Overweight
Apr-30-24	Initiated	JP Morgan	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Jan-29-24	Initiated	Leerink Partners	Outperform
Dec-19-23	Initiated	Wedbush	Outperform
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight

View All

Immunome Inc Stock (IMNM) Latest News

Nov 27, 2024

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference - The Bakersfield Californian

Nov 27, 2024

President of Immunome Picks Up 24% More Stock - Simply Wall St

Nov 27, 2024

Nov 26, 2024

Why Is Immunome Inc (NASDAQ: IMNM) Gaining? - Stocks Register

Nov 26, 2024

Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Analysts - Defense World

Nov 26, 2024

Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Nov 26, 2024

Immunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying Activity - Defense World

Nov 26, 2024

Nov 25, 2024

Immunome's chief medical officer Robert Lechleider buys $149,799 in stock - Investing.com India

Nov 25, 2024